Progress and remaining challenges to address hepatitis C, other infectious diseases, and drug-related harms to improve the health of people who use drugs

Jason Grebely; Alexandra B. Collins; Andreea Adelina Artenie; Rachel Sutherland; Jaimie P. Meyer; Joshua A. Barocas; Oluwaseun Falade-Nwulia; Javier A. Cepeda; Evan B. Cunningham; Behzad Hajarizadeh; Lise Lafferty; Jeffrey V. Lazarus; Matthew Bonn; Alison D. Marshall; Carla Treloar

doi:10.1016/j.drugpo.2021.103469

Progress and remaining challenges to address hepatitis C, other infectious diseases, and drug-related harms to improve the health of people who use drugs

Jason Grebely, Alexandra B. Collins, Andreea Adelina Artenie, Rachel Sutherland, Jaimie P. Meyer, Joshua A. Barocas, Oluwaseun Falade-Nwulia, Javier A. Cepeda, Evan B. Cunningham, Behzad Hajarizadeh, Lise Lafferty, Jeffrey V. Lazarus, Matthew Bonn, Alison D. Marshall, Carla Treloar

Research output: Contribution to journal › Editorial › peer-review

Original language	English (US)
Article number	103469
Journal	International Journal of Drug Policy
Volume	96
DOIs	https://doi.org/10.1016/j.drugpo.2021.103469
State	Published - Oct 2021

ASJC Scopus subject areas

Medicine (miscellaneous)
Health Policy

Access to Document

10.1016/j.drugpo.2021.103469

Cite this

Grebely, J., Collins, A. B., Artenie, A. A., Sutherland, R., Meyer, J. P., Barocas, J. A., Falade-Nwulia, O., Cepeda, J. A., Cunningham, E. B., Hajarizadeh, B., Lafferty, L., Lazarus, J. V., Bonn, M., Marshall, A. D., & Treloar, C. (2021). Progress and remaining challenges to address hepatitis C, other infectious diseases, and drug-related harms to improve the health of people who use drugs. International Journal of Drug Policy, 96, Article 103469. https://doi.org/10.1016/j.drugpo.2021.103469

Grebely, J, Collins, AB, Artenie, AA, Sutherland, R, Meyer, JP, Barocas, JA, Falade-Nwulia, O , Cepeda, JA, Cunningham, EB, Hajarizadeh, B, Lafferty, L, Lazarus, JV, Bonn, M, Marshall, AD & Treloar, C 2021, 'Progress and remaining challenges to address hepatitis C, other infectious diseases, and drug-related harms to improve the health of people who use drugs', International Journal of Drug Policy, vol. 96, 103469. https://doi.org/10.1016/j.drugpo.2021.103469

@article{5751efc803814d0b80b4824b145b1dc9,

title = "Progress and remaining challenges to address hepatitis C, other infectious diseases, and drug-related harms to improve the health of people who use drugs",

author = "Jason Grebely and Collins, {Alexandra B.} and Artenie, {Andreea Adelina} and Rachel Sutherland and Meyer, {Jaimie P.} and Barocas, {Joshua A.} and Oluwaseun Falade-Nwulia and Cepeda, {Javier A.} and Cunningham, {Evan B.} and Behzad Hajarizadeh and Lise Lafferty and Lazarus, {Jeffrey V.} and Matthew Bonn and Marshall, {Alison D.} and Carla Treloar",

note = "Funding Information: The Kirby Institute and the Centre for Social Research in Health are funded by the Australian Government Department of Health . The views expressed in this publication do not necessarily represent the position of the Australian Government. JG is supported by a National Health and Medical Research Council Career Development Fellowship ( 1112352 ). JAB is supported by the National Institute of Health and the National Institute on Drug Abuse ( K01DA051684 and DP2DA051864 ). OFN is supported by the National Institute of Health and the National Institute on Drug Abuse ( K23DA041294 ). JVL acknowledges support to ISGlobal from the Spanish Ministry of Science, Innovation and Universities through the {\textquoteleft}{\textquoteleft} Centro de Excelencia Severo Ochoa 2019-2023{\textquoteright}{\textquoteright} Programme ( CEX2018-000806-S ), and from the Government of Catalonia, Spain, through the CERCA Programme. Funding Information: The Kirby Institute and the Centre for Social Research in Health are funded by the Australian Government Department of Health. The views expressed in this publication do not necessarily represent the position of the Australian Government. JG is supported by a National Health and Medical Research Council Career Development Fellowship (1112352). JAB is supported by the National Institute of Health and the National Institute on Drug Abuse (K01DA051684 and DP2DA051864). OFN is supported by the National Institute of Health and the National Institute on Drug Abuse (K23DA041294). JVL acknowledges support to ISGlobal from the Spanish Ministry of Science, Innovation and Universities through the ??Centro de Excelencia Severo Ochoa 2019-2023?? Programme (CEX2018-000806-S), and from the Government of Catalonia, Spain, through the CERCA Programme.",

year = "2021",

month = oct,

doi = "10.1016/j.drugpo.2021.103469",

language = "English (US)",

volume = "96",

journal = "International Journal of Drug Policy",

issn = "0955-3959",

publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - Progress and remaining challenges to address hepatitis C, other infectious diseases, and drug-related harms to improve the health of people who use drugs

AU - Grebely, Jason

AU - Collins, Alexandra B.

AU - Artenie, Andreea Adelina

AU - Sutherland, Rachel

AU - Meyer, Jaimie P.

AU - Barocas, Joshua A.

AU - Falade-Nwulia, Oluwaseun

AU - Cepeda, Javier A.

AU - Cunningham, Evan B.

AU - Hajarizadeh, Behzad

AU - Lafferty, Lise

AU - Lazarus, Jeffrey V.

AU - Bonn, Matthew

AU - Marshall, Alison D.

AU - Treloar, Carla

N1 - Funding Information: The Kirby Institute and the Centre for Social Research in Health are funded by the Australian Government Department of Health . The views expressed in this publication do not necessarily represent the position of the Australian Government. JG is supported by a National Health and Medical Research Council Career Development Fellowship ( 1112352 ). JAB is supported by the National Institute of Health and the National Institute on Drug Abuse ( K01DA051684 and DP2DA051864 ). OFN is supported by the National Institute of Health and the National Institute on Drug Abuse ( K23DA041294 ). JVL acknowledges support to ISGlobal from the Spanish Ministry of Science, Innovation and Universities through the ‘‘ Centro de Excelencia Severo Ochoa 2019-2023’’ Programme ( CEX2018-000806-S ), and from the Government of Catalonia, Spain, through the CERCA Programme. Funding Information: The Kirby Institute and the Centre for Social Research in Health are funded by the Australian Government Department of Health. The views expressed in this publication do not necessarily represent the position of the Australian Government. JG is supported by a National Health and Medical Research Council Career Development Fellowship (1112352). JAB is supported by the National Institute of Health and the National Institute on Drug Abuse (K01DA051684 and DP2DA051864). OFN is supported by the National Institute of Health and the National Institute on Drug Abuse (K23DA041294). JVL acknowledges support to ISGlobal from the Spanish Ministry of Science, Innovation and Universities through the ??Centro de Excelencia Severo Ochoa 2019-2023?? Programme (CEX2018-000806-S), and from the Government of Catalonia, Spain, through the CERCA Programme.

PY - 2021/10

Y1 - 2021/10

UR - http://www.scopus.com/inward/record.url?scp=85116257136&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85116257136&partnerID=8YFLogxK

U2 - 10.1016/j.drugpo.2021.103469

DO - 10.1016/j.drugpo.2021.103469

M3 - Editorial

C2 - 34610884

AN - SCOPUS:85116257136

SN - 0955-3959

VL - 96

JO - International Journal of Drug Policy

JF - International Journal of Drug Policy

M1 - 103469

ER -

Progress and remaining challenges to address hepatitis C, other infectious diseases, and drug-related harms to improve the health of people who use drugs

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this